Modified Tumor-Targeting Peptide A7R Doubles as Drug Carrier and Tumor Vessel Disruptor
A transmembrane-modified version of tumor-targeting peptide A7R self-assembles into nanoparticles that simultaneously target tumor blood vessels and deliver anti-cancer cargo, reducing tumor growth in mice.
Quick Facts
What This Study Found
Transmembrane-modified A7R peptide self-assembled into nanoparticles that targeted VEGFR2/NRP-1 on tumor vessels, inhibited angiogenesis, and served as a molecular carrier for therapeutic delivery.
Key Numbers
A7R (ATWLPPR) was modified with arginine and glutamic acid substitutions, cyclized, and linked to a membrane-permeation sequence.
How They Did This
Peptide modification and nanoparticle self-assembly characterization. Tested anti-angiogenic and tumor-targeting properties in cell culture and mouse tumor models.
Why This Research Matters
Creating a single molecule that both targets tumor vessels and carries drug payloads simplifies cancer drug design and could improve treatment by combining targeting and therapy in one step.
The Bigger Picture
Most cancer drug delivery systems require separate targeting and payload components. This dual-function peptide approach could simplify nanomedicine design while improving tumor-specific delivery.
What This Study Doesn't Tell Us
Preclinical study. Self-assembly behavior may differ in human blood. Specific therapeutic payload and dosing not fully optimized. Animal model results may not translate directly.
Questions This Raises
- ?Can TM-A7R nanoparticles deliver a range of cancer drugs beyond the ones tested?
- ?How does TM-A7R stability compare to other tumor-targeting peptide systems in vivo?
- ?Would this approach work in human tumors with varying VEGFR2/NRP-1 expression?
Trust & Context
- Key Stat:
- Dual-function peptide TM-A7R simultaneously targets tumor vasculature via VEGFR2/NRP-1 and delivers therapeutic payloads as self-assembled nanoparticles
- Evidence Grade:
- Preliminary evidence: proof-of-concept preclinical study demonstrating novel peptide modification approach for tumor targeting and drug delivery.
- Study Age:
- Published in 2024. Novel approach to dual-function peptide nanoparticle design.
- Original Title:
- Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool.
- Published In:
- Bioorganic chemistry, 145, 107240 (2024)
- Authors:
- Zhang, Qingqing(2), Yang, Zeyu, Zhang, Jie(7), Li, Yanchen, Dang, Xintao, Qu, Jingkun, Pan, Xiaoyan, Zhang, Jie(7)
- Database ID:
- RPEP-09652
Evidence Hierarchy
Frequently Asked Questions
What is A7R peptide?
A7R (ATWLPPR) is a short peptide that specifically targets VEGFR2 and NRP-1 receptors found on tumor blood vessels. By modifying it with a transmembrane segment, researchers enabled it to self-assemble into nanoparticles that both target and disrupt tumor vasculature.
How does this differ from other cancer drug delivery systems?
Most systems use separate targeting and drug-carrying components. TM-A7R does both in a single molecule — targeting tumor vessels while simultaneously serving as the drug carrier, simplifying the design and potentially improving efficiency.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09652APA
Zhang, Qingqing; Yang, Zeyu; Zhang, Jie; Li, Yanchen; Dang, Xintao; Qu, Jingkun; Pan, Xiaoyan; Zhang, Jie. (2024). Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool.. Bioorganic chemistry, 145, 107240. https://doi.org/10.1016/j.bioorg.2024.107240
MLA
Zhang, Qingqing, et al. "Transmembrane modification of tumor vascular targeting peptide A7R as molecular cargo delivery tool.." Bioorganic chemistry, 2024. https://doi.org/10.1016/j.bioorg.2024.107240
RethinkPeptides
RethinkPeptides Research Database. "Transmembrane modification of tumor vascular targeting pepti..." RPEP-09652. Retrieved from https://rethinkpeptides.com/research/zhang-2024-transmembrane-modification-of-tumor
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.